InSilicoMinds Recognised as a Top Contender at The Economic Times AI Awards 2025

Next Blog

Advancing Generic Drug Development Through Model-Integrated Evidence: What to expect from FDA’s Upcoming Workshop?

Model-Integrated Evidence (MIE) is increasingly becoming an important component of science-driven generic drug development. By integrating quantitative modeling and simulation with available in

April 20, 2026

InSilicoMinds has been named a Top Contender at the ET AI Awards 2025 by The Economic Times, India’s first-ever recognition of its greatest AI innovators.

At InSilicoMinds, our mission has always been clear: harness AI, Modeling & Simulation to hyper-accelerate drug development and save lives. This recognition tells us we are on the right path.

The ET AI Awards 2025 Certificate of Achievement recognizes InSilicoMinds (Ikiminds Pvt. Ltd.) on the shortlist of India’s foremost AI innovators. The organization was selected from over 500 nominations, evaluated by EY, and adjudicated by a jury chaired by Dr. Vishal Sikka. To our team, partners, and the pharma community: thank you. The best is yet to come.

Keywords: ,

FDA Works Through ICH to Support Global Drug Development: Creating Harmonized Technical Standards Through Guidelines

May 2, 2024 No Comments

The International Council for Harmonisation (ICH) is a unique project that brings together regulatory authorities and pharmaceutical industry representatives to discuss scientific and technical aspects of pharmaceutical product development and

FDA’s Model-Integrated Evidence (MIE) Industry Meeting Pilot Program for Generic Drugs

January 22, 2024 No Comments

We recently attended, A Deep Dive: FDA’s Model-Integrated Evidence (MIE) Industry Meeting Pilot Program for Generic Drugs Webinar and are excited to share the details with you.

Lipid Nanoparticles and RNA Therapeutics: How In Silico Design is Reshaping the Field

August 7, 2026 No Comments

RNA therapeutics represent one of the most significant shifts in modern medicine. From the rapid development of mRNA COVID-19 vaccines to precision gene silencing and CRISPR-based genome editing, nucleic acid medicines are

Advancing Generic Drug Development Through Model-Integrated Evidence: What to expect from FDA’s Upcoming Workshop?

July 21, 2026 No Comments

Model-Integrated Evidence (MIE) is increasingly becoming an important component of science-driven generic drug development. By integrating quantitative modeling and simulation with available in vitro and in vivo evidence, MIE provides a framework for addressing complex questions

What if you could skip the BE study entirely? With BCS-based biowaivers, you can. 💊

July 8, 2026 No Comments

The Biopharmaceutics Classification System (BCS) allows sponsors to waive in vivo bioequivalence studies for certain oral drug products, replacing them with in vitro dissolution data and, increasingly, PBPK absorption modeling.

Next Blog

Advancing Generic Drug Development Through Model-Integrated Evidence: What to expect from FDA’s Upcoming Workshop?

Related Posts

FDA Works Through ICH to Support Global Drug Development: Creating Harmonized Technical Standards Through Guidelines

FDA’s Model-Integrated Evidence (MIE) Industry Meeting Pilot Program for Generic Drugs

Lipid Nanoparticles and RNA Therapeutics: How In Silico Design is Reshaping the Field

Advancing Generic Drug Development Through Model-Integrated Evidence: What to expect from FDA’s Upcoming Workshop?

What if you could skip the BE study entirely? With BCS-based biowaivers, you can. 💊

Use our AI, Modeling, and Simulation Solutions for Pharma and Life Science

Talk to our In Silico Experts